价格

NAPP PHARMACEUTICALS LIMITED

Unit 191, Cambridge, 英国

概览

试验阶段分布

阶段

试验数

占比

4 期

100.0%

试验状态分布

已完成

100.0%

药物批准

按机构分类的批准

NMPA

National Medical Products Administration

药物批准

EMC

Electronic Medicines Compendium

药物批准

SFDA

Saudi Food and Drug Authority

药物批准

近期批准

Morphine Sulfate Sustained-release Tablets

NMPA

2026-02-25

Morphine Sulfate Sustained-release Tablets

NMPA

2026-02-25

TARGINACT 10MG/5MG PR TABLET

SFDA

2025-07-18

TARGINACT 40MG/20MG PR TABLET

SFDA

2025-07-18

TARGINACT 20MG/10MG PR TABLET

SFDA

2025-07-18

BuTrans 15 microgram/hour transdermal patch

EMC

2025-07-07

OxyContin 5 mg prolonged release tablets

EMC

2025-07-07

Targinact 40 mg/20 mg prolonged-release tablets

EMC

2025-07-07

OxyNorm 5 mg Capsules

EMC

2025-07-07

Palladone SR capsules 8 mg

EMC

2025-07-07

资讯

暂无资讯文章

返回机构列表

NAPP PHARMACEUTICALS LIMITED

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（2）

A Study to Compare Oxycodone/Naloxone Prolonged Release Against Codeine/Paracetamol in the Treatment of Moderate to Severe Chronic Low Back Pain or Pain Due to Osteoarthritis

Buprenorphine in the Treatment of Osteoarthritis (OA) in the Elderly

药物批准

按机构分类的批准

近期批准

资讯